Results 51 to 60 of about 3,663 (172)

Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor

JACC: Case Reports, 2020
A 72-year-old man with coronary artery disease, statin intolerance, and chronic kidney disease stage IIIa was initiated on alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, and developed acute kidney injury.
June K. Pickett, MD, Maulin Shah, MD, Michael Gillette, PharmD, Peter Jones, MD, Salim Virani, MD, PhD, Christie Ballantyne, MD, Vijay Nambi, MD, PhD   +6 more
doaj   +1 more source

Optimization of 4‐Amino‐2‐Pyridone Inhibitors of Proprotein Convertase Subtilisin/Kexin Type 9: Integrating Structure–Activity and Structure–Metabolism Relationships

ChemMedChem, Volume 21, Issue 1, January 2026.
Green chemistry‐based late‐stage functionalization (LSF) of the anti‐proprotein convertase subtilisin/kexin type 9 (PCSK9) early lead compound 5c led to optimized analogs with improved metabolic stability/PCSK9 IC50 ratio. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a key drug target for the treatment of different hypercholesterolemia ...
Lisa Giannessi, Maria Giovanna Lupo, Martina Ugolotti, Bianca Papotti, Beatrice Mattina, Maria Grazia Martina, Anna Demurtas, Cristina Padula, Sara Nicoli, Marco Crescenzio, Nicola Ferri, Francesca Zimetti, Marco Radi   +12 more
wiley   +1 more source

Reduced Serum Soluble L‐Selectin Levels but Not PCSK9 May Be Associated With Generalized Anxiety Disorder: A Case–Control Study

Journal of Clinical Laboratory Analysis, Volume 40, Issue 1, January 2026.
The study included 88 generalized anxiety disorder (GAD) patients and 88 age and sex‐matched healthy controls (HCs). A psychiatrist confirmed the GAD diagnosis, assessed symptom severity using the GAD‐7 scale, and evaluated controls based on the DSM‐5 criteria.
Farzana Akter Munny, Abir Hasan Pranto, Shimanta Paul, Md. Aminul Haque, Rashna Sharmin, Sharifa Sultana, Md. Alamgir Hossain, Md. Rabiul Islam   +7 more
wiley   +1 more source

PCSK9 Modulates the Secretion But Not the Cellular Uptake of Lipoprotein(a) Ex Vivo

JACC: Basic to Translational Science, 2016
To elucidate how the proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitor alirocumab modulates lipoprotein(a) [Lp(a)] plasma levels, the authors performed a series of Lp(a) uptake studies in primary human hepatocytes and dermal fibroblasts and
Elise F. Villard, PhD, Aurélie Thedrez, PhD, Jorg Blankenstein, PhD, Mikaël Croyal, BSc, Thi-Thu-Trang Tran, PhD, Bruno Poirier, PhD, Jean-Christophe Le Bail, PhD, Stéphane Illiano, PhD, Estelle Nobécourt, MD, PhD, Michel Krempf, MD, PhD, Dirk J. Blom, MD, PhD, A. David Marais, MD, Philip Janiak, PhD, Anthony J. Muslin, MD, PhD, Etienne Guillot, PhD, Gilles Lambert, PhD   +15 more
doaj   +1 more source

The Efficacy and Safety of Four Novel PCSK9 Monoclonal Antibodies in Patients With Hypercholesterolemia: A Systematic Review With Network Meta‐Analysis and Trial Sequential Analysis

Cardiovascular Therapeutics, Volume 2026, Issue 1, 2026.
Aim This network meta‐analysis (NMA) evaluated four novel proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies for hypercholesterolemia management, comparing their lipid‐lowering efficacy and safety. Methods We systematically identified randomized controlled trials employing the frequentist NMA method to assess reductions in low ...
Sihua Wang, Chenyu Li, Duncong Fan, Arquimedes Gasparotto Junior   +3 more
wiley   +1 more source

Mortality Benefit of Alirocumab: A Bayesian Perspective [PDF]

Journal of the American Heart Association, 2019
Background The ODYSSEY OUTCOMES (Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome) trial demonstrated that alirocumab reduced major cardiovascular events. However, because of the hierarchical testing strategy used for the multiple outcomes examined, the observed reduction in all‐cause mortality was labeled ...
Christopher Labos, James M. Brophy, Allan Sniderman, George Thanassoulis   +3 more
openaire   +3 more sources

Exploring the Other Side of Medication: A Patient Interview Study on Anti‐PCSK9 Monoclonal Antibodies

Cardiovascular Therapeutics, Volume 2026, Issue 1, 2026.
Background Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors demonstrate significant lipid‐lowering effects, but the widespread use of anti‐PCSK9 monoclonal antibodies remains limited. Purpose This study is aimed at understanding patients′ real‐world experiences with anti‐PCSK9 monoclonal antibodies from a subjective perspective and ...
Ting Zhang, Doudou Li, Yanmei Ning, Jiana Shi, Ying Hu, Irfan Ahmad   +5 more
wiley   +1 more source

Epiafzelechin, a Flavanol, Regulates Lipid Homeostasis Through Modulation of HMGCR, PCSK9, and PPAR‐α: Mechanistic Insights and Therapeutic Implications

Cardiovascular Therapeutics, Volume 2026, Issue 1, 2026.
Hyperlipidemia remains a leading modifiable risk factor for cardiovascular morbidity and mortality. Statins are considered the cornerstone of treatment; however, their adverse effects and limited efficacy in certain patient populations necessitate exploration of novel therapeutic avenues. Epiafzelechin (EZN), a flavanol with established antioxidant and
Saud O. Alshammari, Nazifa Shahzad, Muhammad Nasir Hayat Malik, Qamar A. Alshammari, Abdulkarim Alshammari, Bassam S. M. Al Kazman, Muhammad Atif, Gideon F. B. Solre, Vivek Pandey   +8 more
wiley   +1 more source

Economic aspects of the cardiology program expansion of additional drugs provision by effective lipidlowering drugs for hypercholesterolemia control

Качественная клиническая практика
The federal program of preferential drug provision in cardiology shows its effectiveness. However, hypercholesterolemia (HCH) remains a significant problem in patients in whom high-dose statin therapy does not provide the target level of low-density ...
O. V. Obuhova, A. S. Bogomazova, A. N. Meshkov, M. V. Ezhov   +3 more
doaj   +1 more source

The Role of Lipid Disorders in Cardiovascular Mortality Among Saudis: A Review Perspective

International Journal of Endocrinology, Volume 2026, Issue 1, 2026.
Cardiovascular diseases (CVD) are the main cause of death worldwide and in Saudi Arabia, accounting for about 31% of all deaths globally and 45% of deaths in the Kingdom. The aim of this review was to review the epidemiology, pathophysiology, and management of lipid disorders (mainly dyslipidemia) which are major contributors to CVD in Saudi Arabia ...
Aseel Awad Alsaidan, Suraiya Saleem
wiley   +1 more source